Aristeia Capital L.L.C. Sells 50,625 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Aristeia Capital L.L.C. lessened its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 35.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 94,163 shares of the biopharmaceutical company’s stock after selling 50,625 shares during the period. Aristeia Capital L.L.C. owned 0.18% of Emergent BioSolutions worth $642,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Emergent BioSolutions by 14.7% in the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after purchasing an additional 436,911 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Emergent BioSolutions by 84.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock worth $6,898,000 after buying an additional 1,312,934 shares in the last quarter. American Century Companies Inc. increased its holdings in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after buying an additional 623,201 shares during the period. Marshall Wace LLP raised its position in shares of Emergent BioSolutions by 75.4% in the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after buying an additional 233,341 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of Emergent BioSolutions by 1,314.0% in the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after buying an additional 253,960 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Stock Down 7.5 %

EBS stock opened at $6.06 on Tuesday. The firm has a 50-day moving average price of $9.34 and a 200-day moving average price of $6.23. Emergent BioSolutions Inc. has a 12 month low of $1.42 and a 12 month high of $15.10. The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $317.56 million, a P/E ratio of -0.55 and a beta of 1.60.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. The company had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. During the same period in the previous year, the company earned ($1.06) EPS. As a group, equities research analysts anticipate that Emergent BioSolutions Inc. will post -1.98 EPS for the current fiscal year.

Analyst Ratings Changes

EBS has been the topic of a number of recent analyst reports. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark reiterated a “buy” rating and issued a $8.00 price target on shares of Emergent BioSolutions in a research note on Friday, August 16th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.